Posted On: 05/09/2016 3:51:15 PM
Post# of 373
$RGBP After posting this, I realized I had missed a few other important correlations. The scientific advisory board resume mentions the following(as an isolated excerpt):
"Dr. Lander previously served as interim CEO of MVAX from January 01, 2016 to April 30, 2016 to assist Mr. Dixon with BORIS licensing agreement. "
One word/acronym stuck out: BORIS; Brother of the Regulator of Imprinted Sites. Why is this important? BORIS goes hand in hand with dCellvax, small molecule(NR2F6), Hemaxellerate(as an adjunct for chemo; though also used as a standalone for aplastic anemia as an orphan condition).
Now, after reviewing the above quote one more time, I read this on BORIS:
http://www.prnewswire.com/news-releases/regen...32125.html
If Dr. Lander is assisting Mr. Dixon with licensing, and if Regen mentioned last year an intent to file an IND on BORIS, Molecuvax could be providing the intellectual property and licensing it to Regen for IND, clinicals, and commercialization via sell-off of IP after phase II trials, exactly inline with what Benetic did for Regen in licensing their IP to them for work pertaining to using ddRNA to silence the immuno-suppression caused by Indolamine 2,3--Deoxygenase on dendritic cells. http://www.regenbiopharmainc.com/intellectual-property.html
With Dr. Lander's connections, it seems pretty plausible that he could assist Molecuvax with finalizing the BORIS licensing details, while simultaneously
serving a similar position of oversight at Regen, given that when Harry finishes assisting Mr. Dixon, the product he is working on with "Company A(Molecuvax)" would be contractually passed along to "Company B(Regen)", which then stands to serve both "Companies A and B", with intentions of making both companies profitable via the selling off of the IND'd IP to "Company C(insert name of Big Pharma company here)" who will then take it to the final phase of human clinicals and into the market place, thus paying both entities, as "Company B(Regen)" gets paid by "Company C(Big Pharma company)", and will thus be expected to give a pre-agreed upon percentage to "Company A(Molecuvax)" in exchange for the IP and licensing needed to complete the original IND that was sold off for commercialization to the pharma world post-PhaseII.
"Dr. Lander previously served as interim CEO of MVAX from January 01, 2016 to April 30, 2016 to assist Mr. Dixon with BORIS licensing agreement. "
One word/acronym stuck out: BORIS; Brother of the Regulator of Imprinted Sites. Why is this important? BORIS goes hand in hand with dCellvax, small molecule(NR2F6), Hemaxellerate(as an adjunct for chemo; though also used as a standalone for aplastic anemia as an orphan condition).
Now, after reviewing the above quote one more time, I read this on BORIS:
http://www.prnewswire.com/news-releases/regen...32125.html
If Dr. Lander is assisting Mr. Dixon with licensing, and if Regen mentioned last year an intent to file an IND on BORIS, Molecuvax could be providing the intellectual property and licensing it to Regen for IND, clinicals, and commercialization via sell-off of IP after phase II trials, exactly inline with what Benetic did for Regen in licensing their IP to them for work pertaining to using ddRNA to silence the immuno-suppression caused by Indolamine 2,3--Deoxygenase on dendritic cells. http://www.regenbiopharmainc.com/intellectual-property.html
With Dr. Lander's connections, it seems pretty plausible that he could assist Molecuvax with finalizing the BORIS licensing details, while simultaneously
serving a similar position of oversight at Regen, given that when Harry finishes assisting Mr. Dixon, the product he is working on with "Company A(Molecuvax)" would be contractually passed along to "Company B(Regen)", which then stands to serve both "Companies A and B", with intentions of making both companies profitable via the selling off of the IND'd IP to "Company C(insert name of Big Pharma company here)" who will then take it to the final phase of human clinicals and into the market place, thus paying both entities, as "Company B(Regen)" gets paid by "Company C(Big Pharma company)", and will thus be expected to give a pre-agreed upon percentage to "Company A(Molecuvax)" in exchange for the IP and licensing needed to complete the original IND that was sold off for commercialization to the pharma world post-PhaseII.
(1)
(0)
Do your own DD. Assume everyone here is either an amateur trader/investor or a paid interest such as a compensated pumper/basher. My posts are strictly for entertainment purposes. I am not on Wall St., do not work for a group, and only get paid when my personal investments materialize. I am only responsible for my own gains and losses; no one is to blame for my mistakes or for any advice taken from postings; likewise, I am not to blame for any advice you take of mine, regardless of gains or losses from doing so. Good luck to all; may you live long and prosper greatly.
Scroll down for more posts ▼
